Status:
COMPLETED
Study to Eliminate Hib Carriage in Rural Alaska Native Villages
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborating Sponsors:
CDC-Arctic Investigations Program
Alaska Native Tribal Health Consortium
Conditions:
Haemophilus Influenzae Type B
Carrier State
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Hib disease rates in rural Alaska before introduction of HIb conjugate vaccine were among the highest in the world. Since vaccine introduction, rates have fallen by 90% but the disease has not been el...
Detailed Description
This was a pilot intervention to assess the feasibility of using Hib conjugate vaccine to eliminate Hib carriage in rural Alaska villages, with three villages to serve as a comparison group. WE perfor...
Eligibility Criteria
Inclusion
- All village residents are eligible for Hib colonization survey
- All residents of selected villages eligible for vaccine study except as noted below.
Exclusion
- For receipt of vaccine:
- history of allergic reaction to Hib vaccine or components
- Age \< 24 months and not due for Hib vaccine according to childhood immunization schedule
- Age \> 24 months and have received HIb vaccine within past year
- Pregnant
Key Trial Info
Start Date :
September 1 2001
Trial Type :
INTERVENTIONAL
End Date :
November 1 2003
Estimated Enrollment :
3200 Patients enrolled
Trial Details
Trial ID
NCT00153556
Start Date
September 1 2001
End Date
November 1 2003
Last Update
September 12 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CDC Arctic Investigations Program
Anchorage, Alaska, United States, 99508